Speakers at ASN Kidney Week urge nephrologists to appeal prior authorization denials, include children in trials, and expand access to glomerular disease therapies globally.
|Videos|January 31, 2015
Managed Care Minute: January 31, 2015
A one-minute look back at the week of January 26, 2015, in managed care, including anticipated moves from volume-based to value-based payments and expected push back on cancer drug costs.
Advertisement
This week
Novartis reported that it expects payers will begin to
And lastly, the Joslin Diabetes Center is partnering with The American Journal of Managed Care to bring to life
Advertisement
Related to this article
Jennifer Flythe, MD, MPH, discusses individualizing dialysis volume management and why guideline-directed therapy use lags in advanced CKD.
Povetacicept reduced proteinuria by 52% vs 4.3% with placebo at week 36 in adults with IgA nephropathy in the phase 3 RAINIER trial’s interim analysis.
Outpatient dialysis for unfunded patients with ESKD cut ED reliance and costs, while church-based CKD screening improved blood pressure.
Asian expert consensus updates mantle cell lymphoma treatment guidelines, highlighting uneven BTK inhibitor, ibrutinib and CAR T-cell access across Asia.
At ASN Kidney Week 2026, nephrologists said value-based kidney models improved dialysis starts, but payment cuts and MA growth are pushing practices out.
At IDWeek 2026, IDSA and HIVMA leaders and clinician advocates outline how stories, relationships, and bipartisan outreach shape ID and HIV policy.
At IDWeek 2026, Atul Gawande, MD, MPH, said USAID cuts are costing lives but that the field is "not back at square one."
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Former USAID Health Chief Says Aid Cuts Are Costing Children's Lives
3
How ID, HIV Clinicians Can Influence Policy in an Election Year
4
It’s the Best of Times and Worst of Times for Cancer Care in Tampa
5